Kalvista Pharmaceuticals Inc (NASDAQ:KALV) — Market Cap & Net Worth

$820.37 Million USD · Rank #9795

Market Cap & Net Worth: Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has a market capitalization of $820.37 Million ($820.37 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9795 globally and #2687 in its home market, demonstrating a 0.19% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kalvista Pharmaceuticals Inc's stock price $27.00 by its total outstanding shares 50546293 (50.55 Million). Also see total assets of Kalvista Pharmaceuticals Inc for a full breakdown of the balance sheet.

Kalvista Pharmaceuticals Inc Market Cap History: 2015 to 2026

Kalvista Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $2.56 Billion to $1.36 Billion (-6.14% CAGR). Also see KALV cash generation efficiency for how efficiently the company converts equity into cash flow.

Index Memberships

Kalvista Pharmaceuticals Inc is a constituent of 3 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.66 Trillion	0.03%	#281 of 976
NASDAQ Composite IXIC	$41.74 Trillion	0.00%	#1028 of 3165
NASDAQ Biotechnology NBI	$1.88 Trillion	0.04%	#166 of 263

Weight: Kalvista Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Kalvista Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Kalvista Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Kalvista Pharmaceuticals Inc stock price today for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

52.70x

Kalvista Pharmaceuticals Inc's market cap is 52.70 times its annual revenue

Industry average: 3887.03x Lower than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$357.36 Million	$2.13 Million	-$11.44 Million	167.54x	N/A
2017	$492.83 Million	$1.50 Million	-$18.60 Million	327.68x	N/A
2018	$998.29 Million	$8.39 Million	-$15.80 Million	118.93x	N/A
2019	$900.23 Million	$16.13 Million	-$20.82 Million	55.82x	N/A
2020	$959.87 Million	$12.69 Million	-$29.12 Million	75.64x	N/A
2021	$668.73 Million	$12.69 Million	-$46.24 Million	52.70x	N/A

Competitor Companies of KALV by Market Capitalization

Companies near Kalvista Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Kalvista Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Kalvista Pharmaceuticals Inc by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#186	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$130.44 Billion	$514.63
#353	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$78.29 Billion	$774.11
#457	CSL Ltd	AU:CSL	$59.82 Billion	AU$174.26
#506	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$143.77

Kalvista Pharmaceuticals Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Kalvista Pharmaceuticals Inc's market cap moved from $2.56 Billion to $ 1.36 Billion, with a yearly change of -6.14%.

Year	Market Cap	Change (%)
2026	$1.36 Billion	+67.18%
2025	$816.32 Million	+90.67%
2024	$428.13 Million	-30.86%
2023	$619.19 Million	+81.21%
2022	$341.69 Million	-48.90%
2021	$668.73 Million	-30.33%
2020	$959.87 Million	+6.63%
2019	$900.23 Million	-9.82%
2018	$998.29 Million	+102.56%
2017	$492.83 Million	+37.91%
2016	$357.36 Million	-86.05%
2015	$2.56 Billion	--

End of Day Market Cap According to Different Sources

On Sep 16th, 2026 the market cap of Kalvista Pharmaceuticals Inc was reported to be:

Source	Market Cap
Yahoo Finance	$820.37 Million USD
MoneyControl	$820.37 Million USD
MarketWatch	$820.37 Million USD
marketcap.company	$820.37 Million USD
Reuters	$820.37 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Kalvista Pharmaceuticals Inc

NASDAQ:KALV USA Biotechnology

Market Cap

$1.36 Billion

Market Cap Rank

#9795 Global

#2687 in USA

Share Price

$27.00

Change (1 day)

+0.00%

52-Week Range

$10.76 - $27.00

All Time High

$65.94